Business
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in Hong Kong
OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in Hong Kong.
About this update from Theralink Technologies Inc.
[{"type":"text","content":"\nOncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in Hong Kong \n\nOncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(R) in Hong Kong\n\n\n BATON ROUGE, LA--(Marketwired - April 12, 2016) -  OncBioMune Pharmaceuticals, Inc. (OTCQB: OBMP) (\"OncBioMune\" or the \"Company\"), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, today announces that the Company has received a Notice of Allowance for a patent on ProscaVax®, OncBioMune's cancer vaccine in a Phase 1 trial for relapsed prostate cancer patients, from Hong Kong's patent office.The patent, titled \"Composition and Method for Treating Cancer,\" application number 14101607.7, expands the scope of protection of OncBioMune's intellectual property, which now includes 15 patents and patents pending covering approximately 50 countries worldwide for the Company's vaccine and paclitaxel gallium transferrin (PGT) technologies.ProscaVax is a novel protein therapeutic cancer vaccine combining tumor-associated antigen PSA with biological adjuvants to selectively target tumor cells without damaging healthy cells. OncBioMune is in the process of enrolling and treating the final four patients in a Department of Defense-funded Phase 1a trial of ProscaVax in late-stage cancer patients hosted at the University of California San Diego Moores Cancer Center and Veterans Hospital in La Jolla, California. As recently disclosed, OncBioMune is using the data from the Phase 1a trial, that shows very minimal toxicity of ProscaVax, to forego the Phase 1b portion of the ongoing trial and to initiate two Phase 2 clinical trials of ProscaVax in 2016. One study is planned to be hosted at a major university in the Northeast United States and will enroll early-stage cancer patients in the \"active surveillance\" population. The second, to be conducted in Mexico through a joint venture with Vitel Laboratorios S.A. de C.V., will evaluate ProscaVax for the treatment of PSA recurrent prostate cancer in hormone-naïve and hormone-independent patients.Prostate cancer is the third most common cancer in men in Hong Kong, accounting for approximately 11.1 percent of all newly diagnosed cancer cases annually.\"As we've shown with our recent partners...